Wikipedia

Sinopharm WIBP COVID-19 vaccine

(Redirected from WIBP-CorV)

For other uses, see Sinopharm COVID-19 vaccine.

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV,[2][3] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group).[4] The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

Sinopharm WIBP COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesZhongkangkewei (Chinese: 众康可维)
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status
  • Full and emergency authorizations
Full list of Sinopharm WIBP authorizations
Identifiers
CAS Number
DrugBank

Medical uses

edit

The vaccine is given by intramuscular injection. The administered is 2 doses in 3 weeks.[5][6][7]

Efficacy

edit

In May 2021, peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received the vaccine and 12,737 people received the placebo in these trials.[4]

Manufacturing

edit

In June 2021, a new factory started production with the capacity to manufacture 1 billion doses annually.[8]

History

edit

In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BIBP)[9] and the Wuhan Institute of Biological Products (WIBP).[10] Both vaccines are chemically-inactivated whole virus vaccines for COVID-19.[citation needed]

On August 13, 2020, the Wuhan Institute of Biological Products published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy would require Phase III trials.[10]

Clinical trials

edit

In March 2021, Cayetano Heredia University running the BIBP and WIBP trials in Peru announced they were seeking to suspend and unblind participants in the WIBP trials for lower efficacy and offer the participants the BIBP vaccine instead, which was showing efficacy.[11]

Authorizations

edit
See also: List of COVID-19 vaccine authorizations § Sinopharm WIBP

On February 25, 2021, China approved the vaccine for general use.[12]

According to The New York Times, the vaccine is only approved for limited use in United Arab Emirates.[13] On August 19, 2021, the Philippines approved the vaccine for emergency use authorization.[14]

References

edit
  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine (PDF) (Presentation). World Health Organization. 29 April 2021. Retrieved 10 July 2021. Evaluated BBIBP-CorV & WIBP-CorV
  3. ^ Hadj Hassine I (July 2022). "Covid-19 vaccines and variants of concern: A review". Reviews in Medical Virology. 32 (4): e2313. doi:10.1002/rmv.2313. PMC 8646685. PMID 34755408. S2CID 243939603.
  4. ^ a b Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X (July 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  5. ^ China National Biotec Group Company Limited (29 October 2020). "Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". ClinicalTrials.gov. G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co., Ltd, Beijing Institute of Biological Products Co Ltd.
  6. ^ Universidad Peruana Cayetano Heredia (3 November 2020). "Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru (Covid-Peru)". ClinicalTrials.gov. National University of San Marcos, Peru. NCT04612972.
  7. ^ "Two Chinese-developed COVID-19 vaccines under review". National Medical Products Administration. 25 February 2021. Retrieved 11 April 2021.
  8. ^ "Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses". CNA. Archived from the original on 2021-06-08. Retrieved 2021-06-08.
  9. ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
  10. ^ a b Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X (September 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
  11. ^ "COMUNICADO A LA OPINIÓN PÚBLICA". Universidad Peruana Cayetano Heredia. March 9, 2021.
  12. ^ "China approves two more domestic COVID-19 vaccines for public use". Reuters. 2021-02-25. Retrieved 2021-03-30.
  13. ^ Zimmer C, Corum J, Wee SL (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2021-03-30.
  14. ^ De Vera A (August 25, 2021). "FDA grants EUA to COVID-19 vaccine Sinopharm manufactured by Wuhan affiliate". Manila Bulletin.
edit
 
Scholia has a profile for WIBP-CorV (Q106322660).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sinopharm_WIBP_COVID-19_vaccine&oldid=1247442848"